Propel Bio Management LLC Takes $2.45 Million Position in Jasper Therapeutics, Inc. $JSPR

Propel Bio Management LLC purchased a new position in shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 1,028,806 shares of the company’s stock, valued at approximately $2,449,000. Jasper Therapeutics accounts for approximately 2.5% of Propel Bio Management LLC’s investment portfolio, making the stock its 13th biggest holding. Propel Bio Management LLC owned approximately 6.33% of Jasper Therapeutics at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Readystate Asset Management LP acquired a new position in shares of Jasper Therapeutics in the 3rd quarter valued at $234,000. Vanguard Group Inc. increased its holdings in shares of Jasper Therapeutics by 65.4% during the 3rd quarter. Vanguard Group Inc. now owns 1,032,842 shares of the company’s stock worth $2,458,000 after buying an additional 408,245 shares during the last quarter. Simplify Asset Management Inc. purchased a new position in shares of Jasper Therapeutics in the 3rd quarter worth $1,450,000. Marex Group plc purchased a new position in shares of Jasper Therapeutics in the 2nd quarter worth $74,000. Finally, Engineers Gate Manager LP acquired a new position in Jasper Therapeutics in the second quarter valued at $78,000. Hedge funds and other institutional investors own 79.85% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on JSPR shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jasper Therapeutics in a research report on Thursday, January 22nd. Rodman & Renshaw initiated coverage on shares of Jasper Therapeutics in a report on Tuesday, January 13th. They set a “buy” rating and a $17.00 target price on the stock. Seven equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $19.88.

Jasper Therapeutics Stock Up 6.8%

Shares of Jasper Therapeutics stock opened at $1.42 on Thursday. The firm has a market cap of $39.73 million, a P/E ratio of -0.24 and a beta of 3.08. Jasper Therapeutics, Inc. has a fifty-two week low of $1.11 and a fifty-two week high of $7.19. The business has a 50-day moving average price of $1.51 and a 200 day moving average price of $1.98.

Jasper Therapeutics Profile

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.